- Home
- OCEA vs LGVN Comparison
OCEA vs LGVN Comparison
Compare OCEA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEA
- LGVN
- Stock Information
- Founded
- OCEA 2019
- LGVN 2014
- Country
- OCEA United States
- LGVN United States
- Employees
- OCEA N/A
- LGVN N/A
- Industry
- OCEA Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- OCEA Health Care
- LGVN Health Care
- Exchange
- OCEA Nasdaq
- LGVN Nasdaq
- Market Cap
- OCEA 30.4M
- LGVN 28.4M
- IPO Year
- OCEA N/A
- LGVN 2021
- Fundamental
- Price
- OCEA $0.58
- LGVN $1.65
- Analyst Decision
- OCEA
- LGVN Strong Buy
- Analyst Count
- OCEA 0
- LGVN 3
- Target Price
- OCEA N/A
- LGVN $8.67
- AVG Volume (30 Days)
- OCEA 42.2K
- LGVN 319.6K
- Earning Date
- OCEA 12-24-2024
- LGVN 11-12-2024
- Dividend Yield
- OCEA N/A
- LGVN N/A
- EPS Growth
- OCEA N/A
- LGVN N/A
- EPS
- OCEA N/A
- LGVN N/A
- Revenue
- OCEA N/A
- LGVN $1,852,000.00
- Revenue This Year
- OCEA N/A
- LGVN $161.78
- Revenue Next Year
- OCEA N/A
- LGVN $40.89
- P/E Ratio
- OCEA N/A
- LGVN N/A
- Revenue Growth
- OCEA N/A
- LGVN 141.46
- 52 Week Low
- OCEA $0.52
- LGVN $0.77
- 52 Week High
- OCEA $7.79
- LGVN $21.30
- Technical
- Relative Strength Index (RSI)
- OCEA 29.53
- LGVN 31.55
- Support Level
- OCEA $0.58
- LGVN $1.80
- Resistance Level
- OCEA $0.70
- LGVN $2.15
- Average True Range (ATR)
- OCEA 0.05
- LGVN 0.13
- MACD
- OCEA -0.00
- LGVN -0.03
- Stochastic Oscillator
- OCEA 1.21
- LGVN 0.00
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.